###begin article-title 0
###xml 78 81 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The Mucosae-Associated Epithelial Chemokine (MEC/CCL28) Modulates Immunity in HIV Infection
###end article-title 0
###begin p 1
Conceived and designed the experiments: MC FM EC DB. Performed the experiments: LP DT AC EC LK MB MN. Analyzed the data: MC LP DT EC LK MB MN. Contributed reagents/materials/analysis tools: AC SL FM MS GA CK DT LK JG EL FV MN. Wrote the paper: MC. Other: Designed the study: MC. Wrote the first draft of the paper: MC.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 131 134 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 164 167 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 226 229 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 270 273 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 379 384 <span type="species:ncbi:10090">mouse</span>
CCL28 (MEC) binds to CCR3 and CCR10 and recruits IgA-secreting plasma cells (IgA-ASC) in the mucosal lamina propria (MLP). Mucosal HIV-specific IgA are detected in HIV-infection and exposure. The CCL28 circuit was analyzed in HIV-infected and-exposed individuals and in HIV-unexposed controls; the effect of CCL28 administration on gastrointestinal MLP IgA-ASC was verified in a mouse model.
###end p 3
###begin title 4
Methodology/Findings
###end title 4
###begin p 5
###xml 61 64 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 255 258 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 279 287 <span type="species:ncbi:9606">children</span>
###xml 376 380 <span type="species:ncbi:10090">mice</span>
CCL28 was augmented in breast milk (BM) plasma and saliva of HIV-infected and -exposed individuals; CCR3+ and CCR10+ B lymphocytes were increased in these same individuals. Additionally: 1) CCL28 concentration in BM was associated with longer survival in HIV vertically-infected children; and 2) gastro-intestinal mucosal IgA-ASC were significantly increased in VSV-immunized mice receiving CCL28.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 35 38 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 142 145 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CCL28 mediates mucosal immunity in HIV exposure and infection. CCL28-including constructs should be considered in mucosal vaccines to prevent HIV infection of the gastro-intestinal MLP via modulation of IgA-ASC.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 163 166 163 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Wang1">[1]</xref>
###xml 167 171 167 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Nakayama1">[13]</xref>
###xml 495 498 495 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Hieshima2">[4]</xref>
###xml 500 504 500 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Williams1">[10]</xref>
###xml 637 640 637 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Wang1">[1]</xref>
###xml 642 645 642 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Kunkel1">[5]</xref>
###xml 647 651 647 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Williams1">[10]</xref>
###xml 653 657 653 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Eksteen1">[12]</xref>
###xml 856 859 856 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Hieshima2">[4]</xref>
###xml 861 864 861 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Kunkel2">[6]</xref>
###xml 866 870 866 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Williams1">[10]</xref>
###xml 1150 1153 1150 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Wang1">[1]</xref>
###xml 1154 1157 1154 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Wilson1">[7]</xref>
###xml 1159 1162 1159 1162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Ogawa1">[9]</xref>
###xml 1163 1167 1163 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Eksteen1">[12]</xref>
###xml 1169 1173 1169 1173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Feng1">[14]</xref>
###xml 1175 1179 1175 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Oswald1">[15]</xref>
###xml 1352 1355 1352 1355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Hieshima1">[3]</xref>
###xml 1357 1360 1357 1360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Kunkel1">[5]</xref>
###xml 1362 1366 1362 1366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Nakayama1">[13]</xref>
###xml 1542 1545 1542 1545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Wang1">[1]</xref>
###xml 1546 1550 1546 1550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Nakayama1">[13]</xref>
###xml 1751 1754 1751 1754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Hieshima1">[3]</xref>
###xml 1983 1986 1983 1986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Hieshima1">[3]</xref>
###xml 763 768 <span type="species:ncbi:10090">mouse</span>
###xml 1134 1138 <span type="species:ncbi:10090">mice</span>
###xml 1143 1149 <span type="species:ncbi:9606">humans</span>
Migration of IgA-secreting plasma cells into the mucosal lamina propria (MLP) was recently shown to be correlated with specific chemokines and chemokine receptors [1]-[13]. Thus, IgA-expressing plasma blasts and plasma cells (IgA-ASC) are characterized by a number of surface receptor proteins, including CCR9, CCR3, and CCR10, that are ligated by specific chemokines. In particular, it has been shown that CCR9 ligates the CC chemokine CCL25 (also known as thymus-expressed chemokine, or TECK) [4], [10], whereas both CCR10 and CCR3 bind a second CC chemokine named CCL28 (also known as mucosae-associated epithelial chemokine, or MEC) [1], [5], [10], [12]. These interactions induce the migration and the recruitment of IgA-ASC in the MLP. CCL25 was shown in a mouse model to mostly attract a subpopulation of IgA-ASC associated with the small intestine [4], [6], [10]. CCL28 is more widely expressed and potently chemoattracts IgA-ASC originating from diverse mucosal lymphoid organs, as well as from intestinal and extra intestinal tissues, in every studied mucosal effector site-including the mammary and salivary glands-both in mice and humans [1]-[7], [9]-[12], [14], [15]. Thus, the CCL28-CCR10/CCR3 circuit is considered to be a unifying system that plays a major role in the homing of plasma blasts and plasma cells at mucosal effector sites [3], [5], [13]. Interestingly, these chemotactic abilities are limited to IgA-ASC as the migration of neither IgM nor IgG ASC is stimulated by the CCL28-CCR10/CCR3 or the CCL25-CCR9 systems [1]-[13]. The CCL28-CCR10/CCR3 circuit is also endowed with other interesting peculiarities. Thus, CCL28 has a potent antimicrobial activity directed toward both Gram-positive and Gram-negative microorganisms [3]. Additionally, this chemokine is expressed by bone marrow stromal cells, suggesting that the interaction of CCL28 with CCR10+/CCR3+ B cells may contribute to the integration between the mucosal and the systemic immune responses [3].
###end p 9
###begin p 10
###xml 105 109 105 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Wu1">[16]</xref>
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Soderlund1">[19]</xref>
###xml 239 243 239 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Mazzoli1">[20]</xref>
###xml 244 248 244 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Belec1">[23]</xref>
###xml 435 439 435 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Mazzoli1">[20]</xref>
###xml 440 444 440 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Lizeng1">[24]</xref>
###xml 458 462 458 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Dorrel1">[25]</xref>
###xml 30 33 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 80 83 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 160 163 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 256 259 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 367 370 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 542 545 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 745 748 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 862 865 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1032 1035 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1094 1097 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1183 1186 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1602 1605 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1706 1709 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
High concentration of mucosal HIV-specific IgA have repeatedly been observed in HIV-infected individuals [16]-[19] and have also been suggested to characterize HIV sexually-exposed but uninfected individuals (Exposed Seronegatives or ESN) [20]-[23]. Thus, HIV-specific IgA were described to be present in saliva, cervico-vaginal secretions, and breast milk from both HIV-infected and ESN individuals in Europe, Asia and Africa by most [20]-[24], but not all [25] authors. To investigate whether the presence of high concentrations of mucosal HIV-specific IgA could be explained by an upregulation of the chemokine circuits involved in mucosal homing of IgA-ASC, we first measured CCL25 and CCL28 in breast milk of a well-characterized cohort of HIV-infected breast feeding mothers from Zambia. Results showing a significantly augmented concentration of CCL28 in HIV IgA-positive milk encouraged us to analyze CCR3-, CCR9-, and CCR10-expressing cells as well as the mucosal concentration of CCL25 and CCL28 in ESN subjects and their HIV-infected partners. Results were compared to those seen in HIV-unexposed individuals. Finally, as it was recently shown that the privileged site of HIV replication during primary infection is the gastro-intestinal (GI) mucosa, and IgA could protect this mucosa, we verified whether the administration of CCL28 would result in a significant modulation of IgA in the GI tract using an animal model undergoing immunization with a VSV construct in the presence/absence of CCL28. Results herewith indicate a pivotal role for CCL28 in the modulation of mucosal immunity in HIV exposure and infection and suggest a usefulness of CCL28-containing adjuvants in the development of HIV vaccines.
###end p 10
###begin title 11
Materials and Methods
###end title 11
###begin title 12
Study population
###end title 12
###begin p 13
###xml 114 118 114 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Kuhn1">[26]</xref>
###xml 43 46 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 56 61 <span type="species:ncbi:9606">women</span>
###xml 160 165 <span type="species:ncbi:9606">women</span>
###xml 189 194 <span type="species:ncbi:9606">women</span>
###xml 216 219 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 229 235 <span type="species:ncbi:9606">infant</span>
###xml 360 365 <span type="species:ncbi:9606">women</span>
###xml 397 402 <span type="species:ncbi:9606">women</span>
Breast milk samples were collected from 65 HIV-infected women enrolled in a breastfeeding study in Lusaka, Zambia [26]. The samples were selected to include 15 women who transmitted and 50 women who did not transmit HIV to their infant. Milk samples were collected by manual expression between 1 and 5 weeks post-partum. Milk samples from 9 uninfected Zambian women were included as controls. All women signed informed consent to participate.
###end p 13
###begin p 14
###xml 48 51 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 100 103 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 258 261 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 519 522 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 532 540 <span type="species:ncbi:9606">patients</span>
###xml 542 545 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 643 646 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 692 695 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 705 713 <span type="species:ncbi:9606">patients</span>
###xml 862 865 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Blood samples and saliva were collected from 39 HIV-exposed but uninfected heterosexual partners of HIV-infected individuals (ESN)(27 females; 12 males). The inclusion criteria for the ESN was a history of multiple unprotected sexual episodes (with the same HIV-seropositive partner) for >/=4 years at the time of enrollment, with at least 8 episodes of at-risk intercourse within the 4 months before study entry, and an average of 30 reported unprotected sexual contacts per year (range 18 to >100). Forty age-matched HIV-infected patients (HIV+) and 30 age- and sex-matched healthy volunteer controls (HC), without any known risk factor for HIV-infection, were studied as well. All ESN and HIV-infected patients underwent in-depth clinical and laboratory evaluation that did not reveal any concomitant infectious or gynecologic problems. All individuals (ESN, HIV+, and HC) had been longitudinally followed for >4 years before the study by the Department of Obstetrics and Gynecology, Santa Maria Annunziata Hospital, Florence. This allowed us to exclude from the study ESN and HC in whom sexually transmitted diseases or any other pathology was reported during that time period. Each subject signed an informed consent form that was approved by the Ethical committee of the S. M. Annunziata Hospital.
###end p 14
###begin title 15
Breast milk preparation
###end title 15
###begin p 16
All milk was processed within 4 hours of collection. Milk was centrifuged at 400g and the cell pellet removed. The supernatant and lipid portions were mixed together before aliquoting and were stored at -70degreesC until use.
###end p 16
###begin title 17
Blood sample collection and separation of PBMC
###end title 17
###begin p 18
Whole blood was collected by venipuncture in Vacutainer tubes containing EDTA (ethylenediaminetetraacetic acid) (Becton Dickinson, Rutherford, NJ). Peripheral blood mononuclear cells (PBMC) were separated on lymphocyte separation medium (Organon Teknica, Durham, NC) and washed twice in phosphate-buffered saline (PBS; Organon Teknica). The number of viable leukocytes was determined by trypan blue exclusion. All analyses were performed on freshly collected cells.
###end p 18
###begin title 19
Immunophenotypic analysis
###end title 19
###begin p 20
###xml 213 218 <span type="species:ncbi:10090">mouse</span>
###xml 306 311 <span type="species:ncbi:10090">mouse</span>
###xml 671 675 <span type="species:ncbi:9925">goat</span>
###xml 681 686 <span type="species:ncbi:9606">human</span>
###xml 864 868 <span type="species:ncbi:9925">goat</span>
Surface receptors were evaluated using 50 microl of EDTA peripheral blood. Cells were incubated for 30 min at 4degreesC with the following flourochrome-labeled mAbs: CD19- R-phycoerythrin-Cyanine 5 Tandem-PE-Cy5 (mouse IgG1 isotype, Beckman Coulter, Fullerton CA), CCR3-Phycoerythrin and CCR9-Fluorescein (mouse IgG2a isotype, R&D Systems, Minneapolis, MN). After incubation, erythrocyte lysis and fixation of marked cells was performed using the Immuno-Prep EPICS Kit (Coulter Electronics) and Q-prep Work Station (Coulter Electronics, Miami Lakes, FL).. CCR10 expression was evaluated by indirect immunofluorescence staining on PBMC: by incubating 250,000 cells with a goat anti human CCR10 (diluted 1:25) (Capralogics Inc., Hardwick MA). After 30 min at 4degreesC, the cells were washed and further incubated for 30 min at 4degreesC with 10 microl porcine anti-goat IgG conjugated with PE (R&D Systems, Minneapolis, MN). After this incubation cells were washed and fixed in 1% formaldehyde. Cytometric analyses were performed using an EPICS XL flow cytometer (Beckman-Coulter Inc., Miami, FL) equipped with a single 15 mW argon ion laser operating at 488 nm interfaced with 486 DX2 IBM computer. Data were collected using linear amplifiers for forward and side scatter and logarithmic amplifiers for FL1, FL2 and FL4. Samples were first run using isotype control or single fluorochrome-stained preparations for color compensation. For each sample, multiparametric data were acquired for 100,000 events.
###end p 20
###begin title 21
ELISA assays
###end title 21
###begin p 22
###xml 289 294 <span type="species:ncbi:9606">human</span>
CCL25 and CCL28 concentration was evaluated in breast milk, plasma, and saliva using commercial ELISA kits (R&D Systems, Minneapolis, MN) and following the procedures suggested by the manufacturer. Chemokine production was calculated from a standard curve of the corresponding recombinant human chemokine.
###end p 22
###begin title 23
###xml 15 18 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Measurement of HIV-specific IgA
###end title 23
###begin p 24
###xml 167 171 161 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Kaul1">[21]</xref>
###xml 627 631 621 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Mazzoli1">[20]</xref>
###xml 386 389 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 479 484 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 580 585 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Breast milk concentration of IgA was measured after the thawed stored samples had been centrifuged at 250,00 RCF for 30 minutes at 4degreesC to remove the lipid layer [21]. All samples were processed in the same way without access to information about the other laboratory and clinical parameters. The supernatants were diluted 1:5000 in sterile saline solution or PBS just before use. HIV-specific IgA in breast milk and saliva were measured using a modified Calypte Biomedical HIV-1 enzyme immunoassay (EIA) (Calypte Biomedical Corporation, Berkeley, CA) based on a recombinant HIV-1 envelope protein as previously described [20].
###end p 24
###begin title 25
###xml 15 19 <span type="species:ncbi:10090">mice</span>
Experiments in mice
###end title 25
###begin p 26
###xml 3 19 3 19 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cloning of CCL28</bold>
###xml 30 36 <span type="species:ncbi:10090">murine</span>
1) Cloning of CCL28 The CCL28 murine chemokine gene was digested with AgeI from the pORF-mCCL28 plasmid (InvivoGen, San Diego, CA, USA) and a blunt end was produced with T4 DNA polymerase. Following digestion with NheI, the resulting 410 bp fragment was inserted into pCpG expression vector (InvivoGen), which had been digested with ScaI/NheI.
###end p 26
###begin p 27
###xml 3 18 3 18 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Recombinant VSV</bold>
###xml 79 83 79 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Fuerst1">[27]</xref>
###xml 251 255 251 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Lawson1">[28]</xref>
###xml 332 336 328 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Schnell1">[29]</xref>
###xml 207 221 <span type="species:ncbi:10245">vaccinia virus</span>
2) Recombinant VSV. Recombinant viruses were recovered as described previously [27]. Briefly, BHK-21 cells were grown to 50% confluence and infected at a multiplicity of infection (MOI) of 10 with vTF7-3, a vaccinia virus expressing T7 RNA polymerase [28]. One hour after infection, cells were transfected with 10 microg of pVSVNX2 [29], kindly provided by John Rose (Yale University, New Haven, CT), 3 microg of pBS-N, 5 microg of pBS-P and 2 microg of pBS-L. After 48 h, cell supernatants were added to fresh BHK-21 cells and the recovery of recombinant infectious VSV was performed 48 h later and confirmed by development of cytopathic effect. The recombinant VSV were propagated in BHK-21 cells and stored at -80degreesC.
###end p 27
###begin p 28
###xml 0 27 0 27 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3) Immunization procedures.</bold>
###xml 338 339 338 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 367 368 367 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
###xml 125 130 <span type="species:ncbi:10090">Mouse</span>
###xml 266 270 <span type="species:ncbi:10090">mice</span>
###xml 274 278 <span type="species:ncbi:10090">mice</span>
###xml 340 345 <span type="species:ncbi:10090">mouse</span>
###xml 369 374 <span type="species:ncbi:10090">mouse</span>
###xml 393 398 <span type="species:ncbi:10090">mouse</span>
###xml 434 439 <span type="species:ncbi:10090">mouse</span>
###xml 573 577 <span type="species:ncbi:10090">Mice</span>
3) Immunization procedures. Inbred female BALB mice (Charles River Laboratories, Calco Italy), 6-8 weeks old, were utilized. Mouse colonies were maintained on a 12-h light-dark cycle in cages of 5 animals with water and food provided ad libitum. Different groups of mice (5 mice/group) were immunized as follows: group 1 = VSV alone (1x105/mouse); group 2 = VSV (1x105/mouse)+CCL28 (50 microg/mouse); group 3 = CCL28 alone (50 microg/mouse); group 4 = saline alone (negative control group). VSV was administrated intraperitoneally; CCL28 was administrated intramuscularly. Mice were immunized on day 0, boosted on day 14, and sacrificed on day 28.
###end p 28
###begin p 29
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4) Immunohystochemistry analyses.</bold>
###xml 69 73 <span type="species:ncbi:10090">mice</span>
###xml 677 680 <span type="species:ncbi:10116">rat</span>
###xml 686 691 <span type="species:ncbi:10090">mouse</span>
###xml 892 895 <span type="species:ncbi:10116">rat</span>
###xml 1709 1713 <span type="species:ncbi:9925">goat</span>
###xml 1719 1724 <span type="species:ncbi:10090">mouse</span>
###xml 1898 1902 <span type="species:ncbi:9925">goat</span>
4) Immunohystochemistry analyses. Tissues obtained from the colon of mice (2-cm specimens from the anus toward the left colon) were fixed in buffered-formalin for 24 hours at room temperature and then embedded in paraffin. Haematoxylin-eosin stained sections were used for histological evaluation. The evaluation of CD138+ plasmacells was performed on 3 microm paraffin embedded selides; the sections were dewaxed in xylene, rehydrated in an ascendent ethanol scale and pre-treated in a microwave oven (two cycles for 5 minutes each at 780W, in EDTA buffer, pH8). Endogen biotin and aspecific signals were blocked by using the appropriate reagents. For immunohistochemistry, a rat anti-mouse Syndecan-1 antibody (CD138, dilution 1:250, R&Dsystems, USA) was used; slides were incubated for two hours at room temperature in a humid chamber; washed in PBS and then revealed by biotinylated anti rat IgG (dilution 1:50, one hour incubation, Vector Laboratories, USA) followed by ZyMax Streptavidin HRP Conjugated (dilution 1:500, 30 minutes incubation, Zymed, USA). The chromogen was 3,3'-diaminobenzidine free base (DAB). Negative controls were obtained by omission of the primary antibody. The quantitative evaluation of immunostaining, was performed by counting positive cells in 15 High-Power Fields (the mean of values was considered). The evaluation of IgA+ plasmacells was made on 3 microm paraffin embedded selides; the sections were dewaxed in xylene, rehydrated in an ascendent ethanol scale and pre-treated in a microwave oven (two cycles for 5 minutes each at 780W, in EDTA buffer, pH8). Endogen biotin and aspecific signals were blocked by using the appropriate reagents. For immunohistochemistry, a goat anti-mouse IgA (dilution 1:400, AbD Serotec) was used; slides were incubated for two hours at room temperature in a humid chamber; washed in PBS and then revealed by biotinylated anti goat IgG (dilution 1:50, one hour incubation, R&Dsystems, USA) followed by Streptavidin HRP Conjugated (ready to use, 30 minutes incubation, R&Dsystems, USA). The chromogen was 3,3'-diaminobenzidine free base (DAB).
###end p 29
###begin title 30
Statistical analyses
###end title 30
###begin p 31
Parameters were compared across groups using nonparametric tests (Mann-Whitney) unless normally distributed, in which case two-tailed T-tests were used. Correlations were calculated using the Spearman rank order coefficient. Kaplan-Meier analysis and log-rank testse were used to compare mortality across groups. Statistical analyses were performed using the SPSS statistical package (SPSS Inc. Chicago, Illinois, USA).
###end p 31
###begin title 32
Results
###end title 32
###begin title 33
###xml 10 13 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 47 50 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 60 65 <span type="species:ncbi:9606">women</span>
CCL28 and HIV-specific IgA in breast milk from HIV-infected women
###end title 33
###begin p 34
###xml 697 705 697 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000969-g001">Figure 1</xref>
###xml 203 206 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 216 221 <span type="species:ncbi:9606">women</span>
###xml 276 281 <span type="species:ncbi:9606">women</span>
###xml 397 402 <span type="species:ncbi:9606">women</span>
###xml 410 413 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 423 428 <span type="species:ncbi:9606">women</span>
###xml 514 519 <span type="species:ncbi:9606">women</span>
###xml 533 536 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 611 616 <span type="species:ncbi:9606">women</span>
###xml 634 637 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CCL28 concentrations in breast milk were 2 log higher than that observed in saliva and almost 3 log higher than that observed in plasma Concentrations of CCL28 in breast milk were higher in milk from 65 HIV-infected women (median 288,480 pg/ml) than in milk from 9 uninfected women (median 86,170 pg/ml) but this did not reach significance (p = 0.11) presumably due to small numbers of uninfected women. Among HIV-infected women, CCL28 concentrations in breast milk were nevertheless significantly higher among 34 women who also had HIV-specific IgA detected in their milk (median 354,012 pg/ml) compared to 31 women who did not have HIV-specific IgA detected (median 190,640 pg/ml) (p = 0. 012) (Figure 1).
###end p 34
###begin title 35
###xml 38 41 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 52 55 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 77 82 <span type="species:ncbi:9606">women</span>
CCL28 concentration in breast milk of HIV-infected, HIV-exposed, and healthy women from Zambia.
###end title 35
###begin p 36
###xml 332 334 332 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 344 346 344 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 56 61 <span type="species:ncbi:9606">women</span>
###xml 136 139 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 163 166 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 176 181 <span type="species:ncbi:9606">women</span>
###xml 199 202 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 236 239 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 249 254 <span type="species:ncbi:9606">women</span>
###xml 260 263 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CCL28 concentration (pg/ml) in breast milk from Zambian women enrolled in the Zambia Exclusive Breastfeeding Study (ZEBS). Results from HIV-seronegative controls; HIV-infected women who did not have HIV-specific IgA in breast milk; and HIV-infected women with HIV-specific IgA in breast milk are shown. The boxes stretch from the 25th to the 75th percentile; the line across the boxes indicates the median value; the line stretching from the box reaches the largest and the smallest values detected in each group. Statistically significant differences are indicated.
###end p 36
###begin p 37
###xml 41 44 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 54 59 <span type="species:ncbi:9606">women</span>
###xml 229 234 <span type="species:ncbi:9606">women</span>
###xml 251 254 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 264 271 <span type="species:ncbi:9606">infants</span>
###xml 310 315 <span type="species:ncbi:9606">women</span>
CCL28 concentrations in breast milk from HIV-infected women were not associated with maternal CD4 count, plasma viral load, or breast milk viral load. CCL28 concentrations in breast milk were not statistically different among 15 women who transmitted HIV to their infants (median 288,480 pg/ml) compared to 50 women who did not (median 291,227 pg/ml).
###end p 37
###begin p 38
###xml 111 114 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 124 132 <span type="species:ncbi:9606">children</span>
###xml 147 150 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 160 168 <span type="species:ncbi:9606">children</span>
###xml 304 311 <span type="species:ncbi:9606">infants</span>
###xml 408 411 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 421 429 <span type="species:ncbi:9606">children</span>
A significant association was nevertheless detected between CCL28 concentration in breast milk and survival of HIV-infected children. Among the 15 HIV-infected children, those 7 who died in the first 18 months of life had mothers with lower BM concentrations of CCL28 (median 146,995 pg/ml) than those 8 infants who survived past this age (median 349,472 pg/ml). Based on Kaplan-Meier survival curves, those HIV-infected children whose mothers had CCL28 concentrations less than median in the population (288,480 pg/ml) were more likely to die in the first 18 months of life than those whose mothers had CCL28 concentrations in breast milk greater or equal to the median (log rank p-value  = 0. 038).
###end p 38
###begin title 39
###xml 43 46 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CCL28 in plasma and saliva of ESN, HC, and HIV individuals
###end title 39
###begin p 40
###xml 391 400 391 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000969-g002">Figure 2A</xref>
###xml 57 60 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 90 93 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 222 225 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
###xml 297 300 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CCL28 concentration was measured in plasma of 39 ESN, 40 HIV-infected individuals, and 30 HIV-uninfected healthy controls. Results showed that this IgA-secreting cells chemotactic factor was increased in plasma of ESN and HIV patients compared to HC. Thus, median CCL28 plasma concentrations were HIV = 379; ESN = 332 pg/ml; HC = 185 pg/ml (ESN vs. HC p = 0.039). These results are shown in Figure 2A. In contrast, no differences in the concentration of CCL25 were seen among the three groups of individuals examined (data not shown).
###end p 40
###begin p 41
###xml 266 275 266 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000969-g002">Figure 2B</xref>
###xml 81 84 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 170 173 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 222 225 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 307 310 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The concentration of CCL28 was also significantly increased in saliva of ESN and HIV individuals compared to healthy controls. Median CCL28 salivary concentrations were: HIV = 3379 pg/ml; ESN = 2259 pg/ml; HC = 364 pg/ml (HIV vs. HC p = 0.001; ESN vs. HC p = 0.007)(Figure 2B). CCL25 was comparable in ESN, HIV, and HC (data not shown).
###end p 41
###begin title 42
###xml 44 47 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 58 61 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CCL28 concentration in plasma and saliva of HIV-infected, HIV-exposed, and healthy Italian individuals.
###end title 42
###begin p 43
###xml 66 69 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 113 116 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 151 154 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CCL28 concentration (pg/ml) in plasma (A) and in saliva (B) of 39 HIV-exposed seronegative individuals (ESN), 40 HIV-infected individuals (HC), and 30 HIV-uninfected healthy controls (HC). Median values, standard deviations, and statistically significant differences are indicated.
###end p 43
###begin title 44
###xml 56 59 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CCR3- and CCR10- expressing CD19+ cells in ESN, HC, and HIV individuals
###end title 44
###begin p 45
###xml 443 451 443 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000969-g003">Figure 3</xref>
###xml 331 334 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 335 343 <span type="species:ncbi:9606">patients</span>
Flow cytometry evaluation of CCR3 and CCR10 was performed in CD3+, CD14+ and CD19+ peripheral blood mononuclear cells. Results showed that the CCR3- and CCR10- expressing CD3+ and CD14+ cells were comparable in the three groups examined. In contrast, the percentage of CD19+/CCR3+ and of CD19+/CCR10+ lymphocytes were augmented in HIV patients (p = 0.027 and 0.024, respectively) and in ESN (p = 0.026 and 0.012, respectively) compared to HC (Figure 3). In contrast with these findings, CCR9-expressing lymphocytes were similar in all the individuals analyzed (data not shown).
###end p 45
###begin title 46
Expression of CCR3 and CCR10 on CD19+ B lymphocytes.
###end title 46
###begin p 47
###xml 0 13 0 13 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Upper panels:</underline>
###xml 72 85 72 85 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lower panels:</underline>
###xml 280 283 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 327 330 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 365 368 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Upper panels: CCR3-expressing, CD19+ B lymphocytes in peripheral blood. Lower panels: CCR10-expressing, CD19+ B lymphocytes in peripheral blood. Representative results as well as median values, standard deviations, and statistically significant differences are shown. Thirty-nine HIV-exposed seronegative individuals (ESN), 40 HIV-infected individuals (HC), and 30 HIV-uninfected healthy controls (HC) were analyzed.
###end p 47
###begin title 48
###xml 65 68 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Surface density of CCR3 and CCR10 on CD19+ cells in ESN, HC, and HIV individuals
###end title 48
###begin p 49
###xml 383 391 383 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000969-g004">Figure 4</xref>
###xml 206 209 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 266 269 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 340 343 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Evaluation of the mean fluorescence intensity (MFI), a relative measure of the surface density on a cellular level, revealed that CCR3 MFI on CD19+ cells was significantly augmented in ESN compared to both HIV patients (0.021) and HC (0.034) but was similar between HIV and HC subjects. CCR10 MFI on CD19+ lymphocytes was higher in ESN and HIV compared to HC (ESV vs. HC p = 0.019) (Figure 4). Also in this case, CCR9 MFI was comparable among all groups examined (data not shown).
###end p 49
###begin title 50
CCR3 and CCR10 mean fluorescence intensity on CD19+ B lymphocytes.
###end title 50
###begin p 51
###xml 217 220 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 264 267 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 302 305 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Median fluorescence intensity (MFI). Panel A: CCR3+/CCD19+ B lymphocytes; panel B: CCR10+/CCD19+ B lymphocytes. Median values, standard deviations, and statistically significant differences are indicated. Thirty-nine HIV-exposed seronegative individuals (ESN), 40 HIV-infected individuals (HC), and 30 HIV-uninfected healthy controls (HC) were analyzed.
###end p 51
###begin title 52
###xml 43 46 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Salivary and BM concentration of CCL28 and HIV-specific IgA are correlated
###end title 52
###begin p 53
###xml 73 76 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 111 114 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 197 200 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CCL28 chemoattracts IgA-ASC in the MLP and in the mammary gland; mucosal HIV-specific IgA are observed in both HIV infection and exposure. We verified the presence of possible correlations between HIV-specific IgA and CCL28 both in saliva and BM in the individuals enrolled in the study. Results showed that a significant correlation indeed exists between these two parameters both in saliva (spearman rank order correlation coefficient r = 0.44 p = 0.016) and BM (spearman rank order correlation coefficient: r = 0.26 p = 0. 036).
###end p 53
###begin title 54
###xml 47 51 <span type="species:ncbi:10090">mice</span>
Administration of CCL28 augments rectal IgA in mice
###end title 54
###begin p 55
###xml 55 58 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 86 89 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 330 333 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 443 446 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 497 501 <span type="species:ncbi:10090">mice</span>
The gastro-intestinal MLP is the first site of massive HIV replication during primary HIV infection; this phenomenon is associated with a dramatic early destruction of CD4+ memory T lymphocytes. Elicitation of adaptive mucosal immunity could therefore have an important beneficial effect in the prevention of the establishment of HIV infection. As the results herein showed that increased CCL28 are correlated with augmented concentrations of HIV-specific IgA, we verified whether immunization of mice with a VSV vector in the presence of CCL28 could have resulted in an increase of IgA-ASC in the GI MLP.
###end p 55
###begin p 56
###xml 233 241 233 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000969-g005">Figure 5</xref>
###xml 311 315 <span type="species:ncbi:10090">mice</span>
###xml 492 496 <span type="species:ncbi:10090">mice</span>
###xml 793 797 <span type="species:ncbi:10090">mice</span>
CD138+ plasmacells were clearly identified by a immunopositive staining at the cytoplasmic membrane. Positive cells were localized in the lamina propria of colonic mucosa, isolated or grouped in small clusters. Results, presented in Figure 5, demonstrated that the number of CD138+cells was higher in VSV-CCL28 mice than in saline, VSV-alone, or CCL28 animals. IgA+ plasmacells were identified by immunopositive staining in the cytoplam of cells with plasmacell-like morphology. In VSV+CCL28 mice, IgA+ cells were numerous and grouped in clusters within the lamina propria of colonic mucosa (mean number and S.D. of IgA+ plasmacells = 69+/-17; p vs. all other groups <0.001). In VSV-alone (34+7 IgA+ plasmacells), saline alone (22+15 IgA+ plasmacells), or CCL28 alone (31+13 IgA+ plasmacells) mice, only rare IgA+ cells were identified by immunohistochemistry; they were isolated in the lamina propria of the colon and not clustered. These results suggest a potential usefulness for CCL28 as a mucosal-directed adjuvant.
###end p 56
###begin title 57
###xml 59 63 <span type="species:ncbi:10090">mice</span>
Effect CCL28 on colon plasmacells and IgA of VSV-immunized mice.
###end title 57
###begin p 58
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 138 142 <span type="species:ncbi:10090">mice</span>
###xml 190 194 <span type="species:ncbi:10090">mice</span>
Upper panels: CD138+ plasmacells; Lower panels: IgA+ plasmacells. Left column: Balb/c mice immunized with VSV alone; right column: Balb/c mice immunized with VSV in the presence of CCL28. 5 mice/group were vaccinated. Representative results obtained in the lamina propria of colon mucosa (2-cm specimens from the anus toward the left colon) are presented.
###end p 58
###begin title 59
Discussion
###end title 59
###begin p 60
###xml 124 128 124 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Bomsel1">[30]</xref>
###xml 129 133 129 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Vincent1">[34]</xref>
###xml 224 228 224 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Wu1">[16]</xref>
###xml 229 233 229 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Soderlund1">[19]</xref>
###xml 277 281 277 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Mazzoli1">[20]</xref>
###xml 282 286 282 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Lizeng1">[24]</xref>
###xml 469 473 469 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Clerici1">[35]</xref>
###xml 555 555 555 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Devito1"/>
###xml 555 563 555 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Bomsel2">[36. 37]</xref>
###xml 605 609 605 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Devito2">[38]</xref>
###xml 611 615 611 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Devito3">[39]</xref>
###xml 821 824 821 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Wang1">[1]</xref>
###xml 825 829 825 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Oswald1">[15]</xref>
###xml 158 161 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 211 214 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 238 241 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 288 291 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 444 447 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 940 943 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1091 1094 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1104 1112 <span type="species:ncbi:9606">patients</span>
###xml 1242 1245 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
IgA are mostly mucosal antibodies that are responsible for the first line of defence of adaptive immunity against pathogens [30]-[34]. High concentrations of HIV-specific mucosal IgA have been described in both HIV-infected [16]-[19] and HIV-exposed but uninfected individuals [20]-[24]. HIV-specific IgA seen in these two groups were nevertheless shown to be qualitatively different: IgA of ESN recognize epitopes different from those seen in HIV-infected individuals [35], are capable of inhibiting virus transcytosis through epithelial layers in vitro [36. 37], and have a potent neutralizing activity [38], [39]. These qualitative differences notwithstanding, IgA-secreting plasma cells (IgA-ASC) are chemo-attracted in the mucosal lamina propria by distinctive CC chemokines called CCL28, or MEC, and CCL25, or TECK [1]-[15]. In the attempt to verify whether a correlation does exist between augmented concentrations of mucosal IgA in HIV exposure/infection and increased quantities of CCL28, we measured CCL28, CCL25 and surface expression of CCL28 and CCL25-binding receptors in ESN, HIV-infected patients, and HC. Results shown here indicate that the CCL28-dependent, but not the CCL25-dependent chemotactic circuit is upregulated in HIV exposure and infection, therefore justifying the augmented mucosal concentrations of IgA seen in this condition.
###end p 60
###begin p 61
###xml 180 183 180 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Wang1">[1]</xref>
###xml 184 188 184 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Oswald1">[15]</xref>
###xml 286 289 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1159 1162 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1362 1365 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CCL28 was measured in different mucosal secretions: breast milk and saliva. As CCL28 was repeatedly shown to play a role in the migration of IgA-ASC in mammary and salivary glands [1]-[15] it is not totally unexpected that the concentrations of this factor were higher in both sites in HIV infection and exposure, two conditions characterized by increased IgA concentrations. It could apparently be more surprising that CCL28 was augmented in serum, and that circulating CD19+ cells express more frequently, and at a higher density, CCR3 and CCR10. These results nevertheless become more clear considering that lymphocyte recirculation between tissues and blood compartments is a defining feature of the immune system. The up regulation of CCR3 and CCR10 observed on circulating CD19+ lymphocytes could thus be dependent on the recirculation of lymphocytes between the mucosal and haematic compartments Analogously, the augmented concentrations of CCL28 observed in the mucosal tissues were reflected in the higher quantities of plasmatic CCL28, that, although one fold lower than what is observed in saliva, still showed significant differences when ESN and HIV individuals were compared to healthy controls. It remains to be determined whether the expression of CCR3 and CCR10 in CD19+ lymphocytes isolated from mucosal secretions will be augmented as well in HIV infection and exposure.
###end p 61
###begin p 62
###xml 243 247 243 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Hocini1">[40]</xref>
###xml 778 784 778 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 960 962 960 962 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 1499 1503 1499 1503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Marinda1">[41]</xref>
###xml 111 114 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
###xml 407 410 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 420 428 <span type="species:ncbi:9606">children</span>
###xml 436 444 <span type="species:ncbi:9606">children</span>
###xml 645 648 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 658 666 <span type="species:ncbi:9606">children</span>
###xml 847 850 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 868 875 <span type="species:ncbi:9606">infants</span>
###xml 884 887 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1287 1290 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1367 1375 <span type="species:ncbi:9606">children</span>
###xml 1388 1391 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1443 1451 <span type="species:ncbi:9606">children</span>
IgA are the first and main defensive line used by adaptive immunity at the mucosal level. Not surprisingly, in HIV-infected patients, IgA, but not IgG prevent virus penetration into mucosal targets, thus prevent the establishment of infection [40]. In this light it seems important that CCL28 concentration in breast milk were positively correlated with better survival in Zambian breast-fed and vertically HIV-infected children. These children were enrolled in a protocol (Zambia Exclusive Breastfeeding Study; ZEBS) and randomized to either stop breastfeeding 4 months after birth or to continue breastfeeding. Recent analyses have shown that HIV-infected children who stop breastfeeding had a very high risk of dying shortly after interruption of breastfeeding (Sinkala, M., et al. No benefit of early cessation of breastfeeding at 4 months on HIV-free survival of infants born to HIV-infected mothers in Zambia: the Zambia Exclusive Breastfeeding Study. 14th Conference on Retroviruses and Opportunistic Infections. February 25-28, 2007. Los Angeles, CA.) It could be argued that this mortality is secondary to withdrawal from the positive effect of BM-containing IgA and CCL28 at a time of life when the immune response is still immature. Finally, the correlation between CCL28 and HIV-specific IgA in BM described herein could also justify the observation that children who acquire HIV through breastfeeding have a better prognosis than children who acquire it at delivery or during pregnancy [41].
###end p 62
###begin p 63
###xml 230 234 230 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Brenchley1">[42]</xref>
###xml 235 239 235 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Mattapallil1">[44]</xref>
###xml 379 383 379 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Brenchley1">[42]</xref>
###xml 384 388 384 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Mattapallil1">[44]</xref>
###xml 528 532 528 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Lehner1">[45]</xref>
###xml 534 538 534 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Lehner2">[46]</xref>
###xml 176 179 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 218 221 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 365 368 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 514 517 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 853 857 <span type="species:ncbi:10090">mice</span>
Recent studies have demonstrated that the gut associated lymphoid tissue (GALT) contains the vast majority of T cells in the body, and that GALT is the preferential target for HIV replication during the acute phase of HIV disease [42]-[44]. This phenomenon results in a massive and precocious destruction of CD4+ T cell that strongly impacts on the pathogenesis of HIV infection [42]-[44]. These observations have further strengthened the importance and urgency of developing mucosal vaccine for the prevention of HIV infection [45], [46]. Based on the result shown here, we decided to verify whether immunization in the presence of CCL28 would have had a significant effect on mucosal IgA at the gastro-intestinal (GI) level. This hypothesis was indeed fulfilled by the observation that IgA-ASC were significantly increased in the GI lamina propria of mice that were immunized with VSV in the presence of CCL28. Although preliminary, these results suggest that the use of CCL28 as an adjuvant could result in a beneficial modulation of mucosal immunity. Experiments are in progress in which the biologic effect of CCL28 is further analyzed in animal models.
###end p 63
###begin p 64
###xml 230 233 230 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Wang1">[1]</xref>
###xml 234 238 234 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Oswald1">[15]</xref>
###xml 428 431 428 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Wang1">[1]</xref>
###xml 432 436 432 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000969-Oswald1">[15]</xref>
###xml 837 840 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Tissue-specific migration of lymphocytes is tightly regulated by a complex network of chemokines. CCL28 has been shown to direct homing of ASC to the gastro-intestinal and the upper aero-digestive as well as to the mammary glands [1]-[15]. CCL28 binds to CCR3 and CCR10; CCR10 in particular is considered to be a unifying chemokine receptor that plays a pivotal role in homing of plasmablasts to extra-intestinal effector sites [1]-[15]. The ability of the CCL28-CCR3/CCR10 circuit to chemoattract ASC into multiple mucosal sites has indeed been a founding element of the concept of a common mucosal immune system, and very recent results indicate that CCL28 has a broad and unifying role in the physiology of the mucosal IgA immune system. It might therefore not be surprising that the CCL28 but not the CCL25 circuit is upregulated in HIV infection and exposure.
###end p 64
###begin p 65
###xml 270 273 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The results herein confirm the hypothesis that CCL28 has a hierarchically dominant role in the modulation of adaptive immune responses at the mucosal level and suggest that CCL28 could be useful in the design of mucosal vaccine approaches finalized at the prevention of HIV infection.
###end p 65
###begin title 66
References
###end title 66
###begin article-title 67
Identification of a novel chemokine (CCL28), which binds CCR10 (GPR2).
###end article-title 67
###begin article-title 68
A common mucosal chemokine (mucosae-associated epithelial chemokine/CCL28) selectively attracts IgA plasmablasts.
###end article-title 68
###begin article-title 69
CCL28 has dual roles in mucosal immunity as a chemokine with broad-spectrum antimicrobial activity.
###end article-title 69
###begin article-title 70
CC chemokine ligands 25 and 28 play essential roles in intestinal extravasation of IgA antibody-secreting cells.
###end article-title 70
###begin article-title 71
CCR10 expression is a common feature of circulating and mucosal epithelial tissue IgA Ab-secreting cells.
###end article-title 71
###begin article-title 72
Chemokines in lymphocyte trafficking and intestinal immunity.
###end article-title 72
###begin article-title 73
CCL28 controls immunoglobulin (Ig) A plasma cell accumulation in the lactating mammary gland and IgA antibody transfer to the neonate.
###end article-title 73
###begin article-title 74
T and IgA B lymphocytes of the pharyngeal and palatine tonsils: differential expression of adhesion molecules and chemokines.
###end article-title 74
###begin article-title 75
###xml 47 52 <span type="species:ncbi:9606">human</span>
Regulated production of the chemokine CCL28 in human colon epithelium.
###end article-title 75
###begin article-title 76
Chemokine receptors and leukocyte trafficking in the mucosal immune system.
###end article-title 76
###begin article-title 77
Temporal production of CCL28 corresponds to eosinophil accumulation and airway hyperreactivity in allergic airway inflammation.
###end article-title 77
###begin article-title 78
Epithelial inflammation is associated with CCL28 production and the recruitment of regulatory T cells expressing CCR10.
###end article-title 78
###begin article-title 79
###xml 58 63 <span type="species:ncbi:9606">human</span>
Cutting edge: Profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues.
###end article-title 79
###begin article-title 80
Redundant role of chemokines CCL25/TECK and CCL28/MEC in IgA(+) plasmablast recruitment to the intestinal lamina propria after rotavirus infection.
###end article-title 80
###begin article-title 81
###xml 41 47 <span type="species:ncbi:9913">bovine</span>
Expression of the chemokine CCL28 in the bovine mammary gland.
###end article-title 81
###begin article-title 82
###xml 74 77 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Tropism-restricted neutralization by secretory IgA from parotid saliva of HIV type 1-infected individuals.
###end article-title 82
###begin article-title 83
###xml 46 51 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Plasma and salivary IgA subclasses and IgM in HIV-1-infected individuals.
###end article-title 83
###begin article-title 84
###xml 121 126 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Quantification of IgA and IgG and specificities of antibodies to viral proteins in parotid saliva at different stages of HIV-1 infection.
###end article-title 84
###begin article-title 85
###xml 12 17 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 57 62 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Presence of HIV-1 neutralizing IgA antibodies in primary HIV-1 infected patients.
###end article-title 85
###begin article-title 86
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 46 49 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 75 78 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals.
###end article-title 86
###begin article-title 87
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 42 47 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers.
###end article-title 87
###begin article-title 88
###xml 59 94 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand.
###end article-title 88
###begin article-title 89
###xml 39 74 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 76 81 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 165 170 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 192 197 <span type="species:ncbi:9606">women</span>
Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1 seronegative African women.
###end article-title 89
###begin article-title 90
###xml 52 87 <span type="species:ncbi:11709">human immunodeficiency virus type 2</span>
Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals.
###end article-title 90
###begin article-title 91
###xml 50 53 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Absence of specific mucosal antibody responses in HIV-exposed but uninfected sex workers from the Gambia.
###end article-title 91
###begin article-title 92
###xml 37 40 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 70 77 <span type="species:ncbi:9606">infants</span>
Alpha-defensins in the prevention of HIV transmission among breastfed infants.
###end article-title 92
###begin article-title 93
###xml 60 74 <span type="species:ncbi:10245">vaccinia virus</span>
###xml 92 108 <span type="species:ncbi:10760">bacteriophage T7</span>
Eukaryotic transient expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase.
###end article-title 93
###begin article-title 94
Recombinant vesicular stomatitis viruses from DNA.
###end article-title 94
###begin article-title 95
###xml 102 128 <span type="species:ncbi:11276">vesicular stomatitis virus</span>
The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus J Virol
###end article-title 95
###begin article-title 96
###xml 32 35 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 90 93 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein IgA or IgM.
###end article-title 96
###begin article-title 97
###xml 14 49 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 63 68 <span type="species:ncbi:9606">human</span>
Modulation of human immunodeficiency virus type 1 infection of human monocytes by IgA.
###end article-title 97
###begin article-title 98
###xml 50 85 <span type="species:ncbi:11709">human immunodeficiency virus type 2</span>
###xml 87 92 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection.
###end article-title 98
###begin article-title 99
###xml 46 49 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The role of mucosal immunity in prevention of HIV transmission.
###end article-title 99
###begin article-title 100
###xml 106 111 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 121 129 <span type="species:ncbi:9606">patients</span>
Detection of IgA inhibiting the interaction between gp120 and soluble CD4 receptor in serum and saliva of HIV-1-infected patients.
###end article-title 100
###begin article-title 101
###xml 13 16 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 56 59 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41.
###end article-title 101
###begin article-title 102
###xml 28 33 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 73 78 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 99 104 <span type="species:ncbi:9606">human</span>
Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells.
###end article-title 102
###begin article-title 103
###xml 82 87 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 105 110 <span type="species:ncbi:9606">human</span>
Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells.
###end article-title 103
###begin article-title 104
###xml 12 17 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 84 89 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects.
###end article-title 104
###begin article-title 105
###xml 28 31 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 86 91 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate.
###end article-title 105
###begin article-title 106
###xml 45 48 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160.
###end article-title 106
###begin article-title 107
###xml 0 5 <span type="species:ncbi:9606">Child</span>
###xml 42 48 <span type="species:ncbi:9606">infant</span>
###xml 49 52 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Child mortality according to maternal and infant HIV status in Zimbabwe.
###end article-title 107
###begin article-title 108
###xml 43 46 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CD4+ T Cell Depletion during all stages of HIV Disease Occurs Predominantly in the Gastrointestinal Tract.
###end article-title 108
###begin article-title 109
###xml 67 72 <span type="species:ncbi:9606">Human</span>
Severe CD4+ T cell Depletion in Gut Lymphoid Tissue during Primary Human Immunodeficiebcy Virus Type 1 Infection and Substantial Delay in Restoration following Highly Active Antiretroviral Therapy.
###end article-title 109
###begin article-title 110
###xml 83 86 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection.
###end article-title 110
###begin article-title 111
###xml 88 91 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
European Union and EDCTP strategy in the global context: Recommendations for preventive HIV/AIDS vaccines research
###end article-title 111
###begin article-title 112
###xml 41 44 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Mucosal immunity and vaccination against HIV.
###end article-title 112
###begin p 113
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 113
###begin p 114
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
###xml 280 285 <span type="species:ncbi:9606">Child</span>
###xml 297 302 <span type="species:ncbi:9606">Human</span>
Funding: Supported by grants from the Istituto Superiore di Sanita' "Programma Nazionale di Ricerca sull' AIDS"; Tuscany Region, DG Right to Health and Solidarity Policy; the EMPRO and AVIP EC WP6 Projects; the Japan Health Science Foundation; and from the National Institutes of Child Health and Human Development HD 39611 and HD 40777.
###end p 114

